Plus Therapeutics Stock Price. Everything You Need To Know About The Plus Therapeutics Stock!
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company that’s dedicated to developing innovative treatments for cancer patients. Headquartered in Austin, Texas, the company currently employs 17 full-time employees and has been public since August 9th, 2000.
The company’s primary focus is on developing targeted radiotherapeutics that utilize advanced platform technologies to treat central nervous system (CNS) cancers. Plus Therapeutics’ lead radiotherapeutic candidate, Rhenium (186Re) obisbemeda, has been specifically designed to treat CNS cancers, such as recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC).
Rhenium (186Re) obisbemeda is delivered through direct localized delivery, such as convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters, which utilize approved standard-of-care tissue access. The company’s injectable radiotherapy is designed to deliver targeted, high-dose radiation directly into GBM tumors, providing a potentially effective treatment option for patients.
In addition to Rhenium (186Re) obisbemeda, Plus Therapeutics has also developed 188RNL-BAM, a radioembolization therapy for liver cancer. By developing cutting-edge treatments for cancer patients, Plus Therapeutics is making a significant impact in the healthcare industry. It’s important to stay informed about the latest developments in the industry and keep track of how Plus Therapeutics’ stocks share price today and premarket are performing. By conducting thorough research, investors can make informed decisions about whether Plus Therapeutics is a company that aligns with their investment objectives.
Plus Therapeutics Stock Price. Everything You Need To Know About The Plus Therapeutics Stock! performance
- Employees 17
- Company HQ Austin
- Website http://www.plustherapeutics.com/
- PSTV Asset Type Common Stock
- PSTV Market Capitalization 7.3M
- Earnings Per Share -4.24
- Dividends Per Share None
- Dividend Date 2019-08-06
- Quarterly Earnings Growth 0
Are you interested in investing in the stock market? If you are from Malaysia, Thailand, Indonesia, or Vietnam, we have great news for you! Plus Therapeutics is a stock that you should consider including in your investment portfolio. As an investment platform, Zorion offers you the opportunity to invest in real US stocks, including Pre-IPO companies like Plus Therapeutics. Wondering how to invest in Plus Therapeutics from your country? Zorion provides investment insights and recommendations specifically curated for retail investors in Malaysia, Thailand, Indonesia, and Vietnam. With our resources and educational materials, you can gain the necessary knowledge to make informed investment decisions. Start investing in Plus Therapeutics and explore the potential of the US stock market with Zorion today!
